In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AptarGroup Inc.

www.aptargroup.com

Latest From AptarGroup Inc.

Keeping Track: US FDA Clears Two More Biosimilars, First Non-Injectable Glucagon

The latest drug development news and highlights from our US FDA Performance Tracker.

Approvals Drug Review

Manufacturing Round-Up: FDA Demands Meeting With Aurobindo Over Issues At Multiple Sites

An FDA warning letter issued to Aurobindo highlights recurring failures over several sites, while Teva is setting up a biologics development campus in the US and Nexus is investing in sterile injectables capacity.

Manufacturing Compliance

Start-Up Quarterly Statistics, Q4 2011

Biopharma start-ups raised $693 million in Q4 2011, up 131% from Q3. Device companies brought in $111 million, and diagnostics firms raised $120 million total, $96 million of which was from Biocartis’ Series C. Cancer was the most prevalent therapeutic area for biopharma alliances. And in great contrast to Q3’s one M&A deal involving a start-up company, Q4 saw nine start-up acquisitions.

BioPharmaceutical Medical Device

Deals In Depth: November 2011

Otsuka and Lundbeck signed a long-term CNS collaboration worth $1.4 billion. Gilead spent $10.4 billion on HCV company Pharmasset, the largest amount ever paid for a clinical-stage biotech. Late venture financing and follow-on public offerings represented half of the $945 million that biopharma companies raised. Later-stage rounds were also popular with device companies, which took in $156 million through that financing type, 66% of the $236 million raised.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Nasal
      • Pulmonary
      • Topical Delivery
    • OTC, Consumer
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • AptarGroup Inc.
  • Senior Management
  • Peter Pfeiffer, Pres. & CEO
    Robert W Kuhn, EVP, CFO & Secretary
  • Contact Info
  • AptarGroup Inc.
    Phone: (815) 477-0424
    475 W. Terra Cotta
    Ste. E
    Crystal Lake, IL 60014-9695
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register